ResearcherCross Cancer InstituteNo recent work listed

Angela Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6650-897X; OpenAlex author ID A5043665497. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience. Co-author DOI 10.1177/10781552211038677 ↗
An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel. First author DOI 10.1016/j.clnu.2021.06.026 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Michael B. Sawyer · 2 shared papers, 2021–2022 · strength 0.35
- Paper Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter… DOI 10.1177/10781552211038677 ↗
- Paper An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treat… DOI 10.1016/j.clnu.2021.06.026 ↗
Susie Youn · 1 shared paper, 2021 · strength 0.15
- Paper An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treat… DOI 10.1016/j.clnu.2021.06.026 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.